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Abstract  
 
The involvement of fungi in life-threatening infections has been increasing over the last 
few decades, which can cause death in the terminal stage of patients that have been 
immunocompromised by a malignant tumor, or from contracting hematopoietic system 
diseases, or after receiving strong antitumor treatments. To discern trends in visceral 
mycoses, I have epidemiologically analyzed the data on visceral mycoses that were 
reported in the Annual of the Pathological Autopsy Cases in Japan from 1969 to 2009 
by the Japanese Society of Pathology. In the annual total number of pathological 
autopsy cases, the frequency of visceral mycoses increased noticeably with the 
incidence of candidiasis and aspergillosis increasing the most. Before 1989, visceral 
mycoses were predominantly caused by Candida, followed by Aspergillus. Although 
the rate of candidiasis decreased by degrees from 1990, the rate of aspergillosis 
increased up to, and then surpassed, that of candidiasis. Despite advances in antifungal 
therapy, fungal infections which have fatality rates of 50% to 100% remain a major 
cause of morbidity and mortality in immunocompromised patient. This unmet medical 
need led me to develop a potent antifungal agent, isavuconazole (=RO0094815) which 
is a inhibitor of the lanosterol 14 α-demethylase (CYP51) that catalyzes the formation of 
ergosterol from lanosterol. Isavuconazole showed a potent inhibitory activity against 
fungal pathogens in both in vitro and in vivo models. However, most triazole antifungal 
agents, including isavuconazole, showed only limited activity against zygomycetes spp., 
Fusarium spp., Pseudallescheria spp., Sporothrix spp., and Scedosporium ssp. This 
limitation is a major drawback of azoles. 
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The following text in the abstract has been omitted pending regulatory approval of 
Isavuconazole. 
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Abbreviations 
 
AIDS Aquired immune deficiency syndrome 
ALL Acute lymphatic leukemia 
AmB Amphotericin B 
AML Acute myeloid leukemia 
ATCC American Type Culture Collection 
ATL Adult T cell leukemia  
BMT Bone marrow transplantation 
BSI Bloodstream infection 
CLL Chronic lymphatic leukemia 
CLSI Clinical Laboratory Standards Institute   
CML Chronic myeloid leukemia 
CYP51 CYP51 Cytochrome P450 sterol C14α-demethylase  
 (=lanosterol 14α-demethylase) 
DIC Disseminated intravascular coagulation 
ERG11 = CYP51  
FLC Fluconazole 
ICD-9 the International Classification of Diseases 9 
ICD-10 the International Classification of Diseases 10  
ITC Itraconazole 
MDS Myelodysplastic syndrome 
MIC Minimum inhibitory concentration 
MoL Monocytic leukemia 
NCBI National Center for Biotechnology Information 
NCCLS National Committee for Clinical Laboratory Standards 
OD Optical density 
PK Pharmacokinetics 
RO0094815 Isavuconazole 
VRC Voriconazole  
 
 
4 
 
General introduction  
 
Fungi are non-photosynthetic eukaryotic organisms with well defined nuclei 
and characteristic intracellular membrane-bound organelles such as endoplasmic 
reticulum, golgi apparatus, lysosome, and mitochondria, etc. Most fungi species are 
heterotrophic or saprophytic and are responsible for the breakdown of organic material 
in environments. Fungi comprise a very large and diverse group of microorganisms that 
chiefly exist as mycelia, the threadlike branching hyphae that form the fluffy structure 
usually seen on moldy food, and fungi in mycelial form are known as molds. The shape 
of these tube-like structures is maintained by apical growth and the presence of a robust 
cell wall composed of several kinds of polysaccharides. Although most fungi exist with 
mycelial growth, many species have a life-cycle stage as unicellular or yeast form. 
Growth of these cells results from budding at a specific site or at the site of separation 
of daughter cells from mother cells. Mushrooms are an example of Basidiomycotina 
fungi that has fruiting bodies.   
In a recent classification, both Fungi and Metazoa (animals) belong to 
Opisthokonta, one of the 6 major eukaryotic supergroups (104), whereas land plants, 
which belong to the Archaeplastida supergroup, are only distantly related to 
Opisthokonta. Although the distantly-related fungi and land plants both possess cell 
wall, animals, the relative of fungi do not. The cell wall of fungi contains β-D-glucan, 
chitin, chitosan, and mannan, while the major components of the cell wall of land plants 
are cellulose, hemicellulose, and pectin. The cell membrane of all eukaryotic organisms 
is generally about 5 nm thick and contains phospholipids, sterols, and proteins that 
together form a lipid bilayer structure. Membrane sterols of fungi consist cheifly of 
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ergosterol and its derivatives, but those of animal cells consist of cholesterol. This is the 
most important difference between animal and fungal cells.  
We often suffer from infection by pathogenic fungi or, in immunocompromised 
settings, by opportunistic fungi.  About 200 species of fungi are known to be 
pathogenic to humans and animals, and some fungi also cause plant diseases. The most 
notable mycosis (fungal infection) agents of human visceral infection belong to three 
fungal groups, ascomycetes, basidiomycetes and zygomycetes. Candida and Aspergillus 
are major genus of the ascomycetes, Cryptococcus is in basidiomycetes, and the Mucor 
and Rhizopus species are zygomycetes. In the past few decades, interest in human 
mycoses has surged as a result of a significant increase in the relative importance of 
fungal infections in the western world. Factors predisposing humans to fungal infections 
are: congenital immune defects, diabetes, human immunodeficiency virus (HIV) 
infection, and malignant diseases. The incidence of fungi in life-threatening infections 
has been increasing, and severe visceral mycosis in particular is a cause of death in the 
terminal stage of immunocompromised patients who have suffered from a malignant 
tumor or a hematopoietic system disease, or have received strong antitumor treatment. 
Although some patients tend to be living longer due to recent advanced medical 
treatments, such as organ transplantation or hematopoietic stem cell transplantations 
with immunosuppressant treatments or radiation therapy and chemotherapy in cancer 
and leukemia settings, those patients still have a high risk of suffering from fungal 
infections because of their immunocompromised state. 
Unfortunately, there have been very few reports of quantitative analyses on 
visceral mycoses and, even though mycoses are known to have increased, the trends of 
infections, their causative agents, underlying diseases, and gender of patients were not 
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noted in detail. Such epidemiological data is fundamental information and is a precious 
resource for deciding promptly what measures to take; therefore, an analysis of 
epidemiological trends of mycoses in the clinical setting in Japan would be 
indispensable. 
An important strategy in preventing high-risk patients from fungal infections is 
treatment with antibiotics and antifungals prophylactically or empirically but, although 
many effective antibiotics and antibacterial agents are on the market, there are few 
effective antifungals. The only antifungal drugs available for systemic use in Japan are 
amphotericin B (AmB) (polyene macrolide analog) as a plasma membrane-disrupting 
agent; fluconazole (FLC), itraconazole (ITC) and voriconazole (VRC) (which are all 
triazole analogs) as inhibitors of ergosterol (a component of plasma membrane) 
synthesis; terbinafine (an allylamine analog) as an inhibitor of squalene epoxidase; and 
fluorocytosine as an inhibitor of DNA synthesis. Using these drugs to treat mycoses in 
humans ordinarily encounters problems of resistance and toxicity. Therefore, it is highly 
desirable to make a better antifungal agent with a broad antifungal spectrum that 
includes strains resistant to the antifungals already on the market, and that has good PK, 
high selectivity, and less toxicity to humans.  
In part I, to outline the trend in systemic mycoses in Japan, I epidemiologically 
analyzed the data on visceral mycoses reported in the Annual of the Pathological 
Autopsy Cases in Japan over the past 40 years. From this analysis, I realized that total 
visceral mycoses have been increasing, and that aspergillosis in particular had increased 
remarkably. Furthermore, I recognized the major underlying diseases that pose the 
highest risk for patients who have been exposed to some predisposing factors. From 
these results, unmet medical needs for developing new antifungals were suggested.  
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 In part II, I have compared the antifungal activity of isavuconazole, a 
lanosterol 14α-demethylase (CYP51) inhibitor that was screened from hundreds of 
synthesized triazole derivatives, against 140 reference fungal strains and 165 clinically 
isolated yeasts in Japan and compared the results with those of other azoles and AmB. I 
showed the inhibitory activity of isavuconazole and discussed the species that are 
intrinsically resistant to triazole antifungals in a framework of fungal phylogeny and 
evolution. 
At present, this potent antifungal drug that was developed as a result of this 
research is now in clinical phase III studies in the US. Some studies have been 
completed and the latest result of one study has met the primary endpoint.  
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Part I 
 
Epidemiology of Visceral Mycoses: Analysis of Data in Annual of the 
Pathological Autopsy Cases in Japan 
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Abstract 
 
The data on visceral mycoses that had been reported in the Annual of the Pathological 
Autopsy Cases in Japan from 1969 to 2009 by the Japanese Society of Pathology were 
analyzed epidemiologically. The frequency of visceral mycoses among the annual total 
number of pathological autopsy cases increased noticeably from 1.60% in 1969 to a 
peak of 4.66% in 1990. Of them, the incidences of candidiasis and aspergillosis 
increased the most. After 1990, however, the frequency of visceral mycoses decreased 
gradually. Until 1989, the predominant causative agent was Candida, followed in order 
by Aspergillus and Cryptococcus. Although the rate of candidiasis decreased by degrees 
from 1990, the rate of aspergillosis increased up to and then surpassed that of 
candidiasis in 1991. After 1994, the rate of mycoses increased again and the frequency 
of aspergillosis also rose. In the 10 years between 1999 and 2009, the frequency of 
visceral mycoses varied between 4.01 and 4.70% with a peak in 2009. The major 
disease underlying the visceral mycoses was leukemia, followed by solid cancers and 
then by other blood and hematopoietic system diseases. Severe mycotic infection 
increased over the reported 25-year period from 6.6% of the total visceral mycosis cases 
in 1969 to 71% in 1994. But during the decade after 1994, severe infections decreased 
by degrees to between 40% and 50%, as did Candida infections. The reasons for this 
decrease of candidiasis combined with increase of aspergillosis and of severe mycotic 
infection in general might be that (i) both non-severe and severe Candida infections 
were excluded from the case totals when it became possible to control them by 
antifungal drugs such as FLC and ITC, but (ii) the available antifungal drugs were not 
efficacious against severe infections, such as pulmonary aspergillosis or central nervous 
system infections by zygomycetes species, and (iii) the number of patients living longer 
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in an immunocompromised state had increased because of developments in 
chemotherapy and progress in medical care. These epidemiological findings strongly 
suggested that novel effective antifungals are necessary to treat severe fungal infections, 
such as aspergillosis and drug-resistant candidiasis.   
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Introduction 
 
Recently many reports have described an increase of systemic fungal infections, 
such as aspergillosis (13, 23), zygomycosis (17), fusariosis (98), and candidiasis due to 
non-albicans Candida species (15). It seems possible to control cutaneous or superficial 
candidiasis by using effective azoles; however, azole-resistant C. albicans strains and 
pathogenic non-albicans Candida species have been emerging (8, 15, 100). Furthermore, 
severe systemic aspergillosis has been increasing in bone marrow transplant patients (7) 
and in those with other immunocompromised conditions (6).  
Over the past 40 years, medical mycologists and pathologists have published 
several papers on the trends of mycoses (23, 27, 67, 87, 92, 93). Groll et al. reported the 
trends of invasive fungal infections from autopsy findings at the university hospital of 
Frankfurt, Germany (22, 23), and Kappe et al. presented analyzed data for invasive 
aspergillosis cases culled from autopsy records in Heidelberg, Germany (68). In Japan, 
several studies analyzing data on mycoses from autopsies were reported previously, but 
reports on recent trends are few. A study by Miyake and Okudaira covered the 13 years 
between 1948 and 1961 (87), and a study by Hotchi et al. covered the 10 years between 
1966 and 1975 (27). Okudaira et al. then reported the analyzed data from 1972 to 1981 
(93), and now this report covers the periods after that. As I know wanted to know the 
impact of FLC and ITC launching, I concentrated my study on the period after 1989. 
To discern current trends in visceral mycoses, I have epidemiologically 
analyzed the data on visceral mycoses that had been reported in the Annual of the 
Pathological Autopsy Cases in Japan, from 1969 to 2009 (31-66). A total numbers of 
mycosis cases was increasing until 1990, whereas the number of candidiasis cases 
stopped increasing and began to decrease after 1989 (75, 77), chiefly because of the 
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effects of a newly developed antifungal drug, FLC. Aspergillosis cases, on the other 
hand, were not decreasing but came to have the highest rate of mycosis among the total 
autopsies. In this report, I review the recent trends and also analyze the effect of 
antifungal agents introduced in the clinical settings. 
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Materials and Methods 
 
Diagnostic criteria  
The criteria for the pathological diagnosis of each class of mycosis described in 
the Annual of the Pathological Autopsy Cases in Japan are not defined definitively by 
the Japanese Society of Pathology. Basically, the description of each case is the 
responsibility of the reporting pathologist and depends on his or her ability to make a 
diagnostic determination. Most of the autopsies included both gross and 
histopathological examinations, but it cannot be expected that all pathologists were 
equally rigorous in their examination, and some differences may have been derived 
from their individual experiences of mycoses. Concerning fungemia or candidemia, 
reporting pathologists might have been given some clinical information on fungemia 
from the patient’s medical records. Although I could not exclude any ambiguities on 
these diagnostic data, I used the original descriptions to define the class of mycosis for 
each case. 
 
Definitions  
Mycoses were defined as infections caused by eumycotic organisms such as 
Candida, Aspergillus, Cryptococcus, Zygomycete, and other fungal species. Infections 
caused by filamentous bacteria such as Actinomycetes (Actinomadura, Nocardia, and 
Streptomyces spp.) and pneumocystis pneumonia caused by Pneumocystis jirovecii 
were excluded from the criteria for mycoses. Superficial infections such as 
dermatophytoses were excluded from the category of visceral mycoses. The term 
“complicated infection” means a mixed infection with two or more species of fungi, as 
when cultures from specimens might be identified as containing more than two kinds of 
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fungi.  
Mycotic infections from the autopsy records were defined as severe if they 
were (i) the direct cause of death; (ii) severe pulmonary infection involving both lobes 
of the lung; (iii) severe visceral infections of two or more organ systems, including 
those involving the central nervous system; (iv) multiorgan systemic infection of three 
or more organ systems; or (v) fungemia. 
 
Data collection  
The data for annual total deaths and the number of certified deaths from 
mycoses were taken from Vital Statistics of Japan, edited from 1969 to 1996 by the 
Minister’s Secretariat, Ministry of Health and Welfare (105). And further years of data 
from 1997 to 2009 were collected from the database edited by the National Statistics 
Center, the Ministry of Internal Affairs and Communication (108).  
Data on visceral mycoses occurring in Japan from 1969 to 2009 were collected 
in the Annual of the Pathological Autopsy Cases in Japan, which was published from 
1970 to 2010 by the Japanese Society of Pathology (31-66). Those data were extracted 
and compiled to make a database for analysis; however, data from the years 1982 to 
1988 other than 1985 were not used in this study because they were not available. Cases 
of stillborn babies were excluded from each annual total number of autopsy cases. The 
data were compiled into a database by using Filemaker Pro version 5.0, supplied by 
Filemaker, Inc., and used to look up causative agents of infection, age, sex, underlying 
diseases, and infected organs of patients. 
 
  
 
 
15 
 
Results 
 
In recent years, the annual total number of deaths in Japan has been about 
1,000,000, and of these, about 1.5 to 4% of bodies are examined by pathological 
autopsy annually. FIG. 1 shows that among the total deaths, the frequency of mycotic 
infection (that is, of candidiasis, aspergillosis, or other fungal infections) as the certified 
direct cause of death had increased noticeably from 1979 to 2009. Before 1994, diseases 
were classified using the International Classification of Diseases 9 (ICD-9) as the 
standard diagnostic tool for epidemiology, which did not provide a list of causative 
agents in detail. The list of fungal causative agents in ICD-10 includes not only Candida 
but also Aspergillus and other fungi. After 1994, Aspergillus infections have suddenly 
and dramatically increased.  
 
 
 
The occurrence of mycoses among total autopsy cases from 1969 to 2009 in 
year
FIG.1 Annual trends of total death and of deaths certified as resulting from mycoses in Japan. Data were extracted from Vital Statistics of 
Japan, edited by the National Statistics Center, the Ministry of Internal affairs and Communication for the years 1969 through 2009.
, number of annual total deaths;      candidiasis cases;         aspergillosis cases;         other mycoses cases.
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Japan, excluding data from 2006 and 2008, is shown in TABLE 1.  
 
TABLE 1.  Change in rates of mycoses among total autopsy cases and of causative agents of mycoses 
from 1969 to 2009 in Japan 
a An unidentified hungus was observed in the infected organ. 
b Mixed infection with two or more than two kinds of fungi in the infected organ. 
 
The frequency of visceral mycoses in the annual total number of autopsy cases 
increased significantly from 1.60% in 1969 to a peak of 4.66% in 1990. After 1990, 
however, this frequency decreased gradually, from 3.79% in 1991 to 3.17% in 1994. 
After 1994, the mycoses rate increased again and during the 10 years between 1999 and 
2009, the frequency of visceral mycoses fluctuated between 4.01 and 4.70%, with a 
peak in 2009. Candidiasis also increased from 0.41% in 1969 to a peak of 1.89% in 
1989 and then decreased to around 1.3% by degrees after 1991. In contrast, the 
aspergillosis rate rose from 0.39% in 1969 to a peak of 2.1% in 2001 and has 
maintained a constant level of about 1.9% from 1999. During this period, the rate of 
zygomycosis increased slowly (ranging from 0.01% to 0.22%), whereas that of 
1969 24,715 396 1.60 25.8 (0.41) 24.5 (0.39) 8.8 (0.14) 0.8 (0.01) 0.3 (0.00) 37.6 (0.60) 2.3 (0.04)
1970 23,599 407 1.72 27.0 (0.47) 21.1 (0.36) 9.6 (0.17) 4.7 (0.08) 0.5 (0.01) 34.6 (0.60) 2.5 (0.04)
1971 23,245 433 1.86 28.9 (0.54) 24.7 (0.46) 9.9 (0.18) 3.7 (0.07) 0.2 (0.00) 28.9 (0.54) 3.7 (0.07)
1972 22,769 379 1.66 38.8 (0.65) 31.7 (0.53) 14.0 (0.23) 2.9 (0.05) 0.0 (0.00) 7.7 (0.13) 5.0 (0.08)
1973 23,274 466 2.00 37.8 (0.76) 23.4 (0.47) 12.7 (0.25) 1.3 (0.03) 0.0 (0.00) 21.7 (0.43) 3.2 (0.06)
1974 23,111 531 2.30 35.4 (0.81) 22.6 (0.52) 8.5 (0.19) 1.9 (0.04) 0.2 (0.00) 27.9 (0.64) 3.6 (0.08)
1975 23,048 620 2.69 34.5 (0.93) 17.3 (0.46) 8.1 (0.22) 2.9 (0.08) 0.0 (0.00) 34.5 (0.93) 2.7 (0.07)
1976 24,093 621 2.58 43.0 (1.11) 21.4 (0.55) 9.5 (0.24) 2.3 (0.06) 1.1 (0.03) 18.4 (0.47) 4.3 (0.11)
1977 25,897 664 2.56 37.5 (0.96) 22.6 (0.58) 6.9 (0.18) 3.5 (0.09) 0.2 (0.00) 25.3 (0.65) 4.1 (0.10)
1978 30,742 813 2.64 43.1 (1.14) 23.2 (0.61) 8.2 (0.22) 3.3 (0.09) 1.8 (0.05) 16.9 (0.45) 3.4 (0.09)
1979 32,844 861 2.62 35.4 (0.93) 21.7 (0.57) 9.1 (0.24) 3.0 (0.08) 0.0 (0.00) 25.9 (0.68) 4.9 (0.13)
1980 35,943 970 2.70 49.2 (1.33) 20.7 (0.56) 7.3 (0.20) 3.2 (0.09) 0.0 (0.00) 15.1 (0.41) 4.5 (0.12)
1981 38,841 1,096 2.82 42.0 (1.18) 26.0 (0.73) 7.4 (0.21) 3.8 (0.11) 0.1 (0.00) 15.0 (0.42) 5.7 (0.16)
1985 39,333 1,558 3.96 41.6 (1.65) 30.7 (1.22) 6.5 (0.26) 3.6 (0.14) 0.8 (0.03) 11.0 (0.44) 5.7 (0.23)
1989 37,557 1,672 4.45 42.3 (1.89) 30.1 (1.34) 5.4 (0.24) 3.6 (0.16) 0.2 (0.01) 13.0 (0.58) 5.1 (0.23)
1990 37,399 1,743 4.66 33.6 (1.57) 33.2 (1.55) 4.8 (0.22) 3.5 (0.16) 0.1 (0.00) 20.7 (0.96) 4.1 (0.19)
1991 35,618 1,350 3.79 33.7 (1.28) 34.7 (1.32) 4.7 (0.18) 3.6 (0.13) 0.0 (0.00) 19.2 (0.73) 4.1 (0.16)
1992 33,201 1,177 3.55 36.3 (1.29) 37.3 (1.32) 5.4 (0.19) 4.2 (0.15) 0.0 (0.00) 12.3 (0.44) 4.4 (0.16)
1993 31,207 1,136 3.64 37.2 (1.36) 36.5 (1.33) 4.5 (0.16) 3.4 (0.12) 0.3 (0.01) 14.5 (0.53) 3.5 (0.13)
1994 27,827 882 3.17 35.5 (1.12) 40.7 (1.29) 6.1 (0.19) 3.2 (0.10) 0.1 (0.00) 10.4 (0.33) 4.0 (0.13)
1995 27,926 1,022 3.66 31.0 (1.14) 39.8 (1.46) 6.8 (0.25) 3.7 (0.14) 0.2 (0.01) 15.1 (0.55) 3.3 (0.12)
1996 27,058 1,060 3.92 32.1 (1.26) 41.2 (1.62) 5.0 (0.20) 3.8 (0.15) 0.2 (0.01) 14.2 (0.56) 3.5 (0.14)
1997 26,681 1,143 4.28 34.7 (1.49) 40.9 (1.75) 3.8 (0.16) 3.6 (0.15) 0.2 (0.01) 13.5 (0.58) 3.2 (0.14)
1998 25,961 1,135 4.37 30.3 (1.33) 43.2 (1.89) 4.5 (0.20) 2.8 (0.12) 0.2 (0.01) 15.2 (0.67) 3.8 (0.17)
1999 27,194 1,243 4.57 29.0 (1.32) 43.5 (1.99) 4.5 (0.21) 2.3 (0.11) 0.0 (0.00) 16.7 (0.76) 3.9 (0.18)
2000 26,159 1,051 4.02 30.4 (1.22) 50.7 (2.04) 7.0 (0.28) 3.4 (0.14) 0.0 (0.00) 4.4 (0.18) 4.0 (0.16)
2001 25,459 1,165 4.58 27.4 (1.25) 46.0 (2.10) 5.3 (0.24) 3.5 (0.16) 0.3 (0.01) 14.1 (0.65) 3.4 (0.16)
2002 24,010 976 4.06 27.2 (1.10) 49.1 (2.00) 4.5 (0.18) 2.6 (0.10) 0.2 (0.01) 11.2 (0.45) 5.3 (0.22)
2003 20,948 841 4.01 32.7 (1.31) 45.1 (1.81) 6.2 (0.25) 3.2 (0.13) 0.0 (0.00) 9.2 (0.37) 3.7 (0.15)
2004 19,930 843 4.23 29.5 (1.25) 44.1 (1.87) 6.6 (0.28) 3.9 (0.17) 0.4 (0.02) 12.1 (0.51) 3.3 (0.14)
2005 18,924 872 4.61 28.3 (1.31) 43.3 (2.00) 5.5 (0.25) 4.5 (0.21) 0.2 (0.01) 14.0 (0.64) 4.1 (0.19)
2007 16,384 720 4.39 27.6 (1.21) 45.0 (1.98) 6.1 (0.27) 5.0 (0.22) 0.6 (0.02) 12.6 (0.56) 3.1 (0.13)
2009 13,787 648 4.70 27.9 (1.31) 44.6 (2.10) 5.4 (0.25) 3.9 (0.18) 0.3 (0.01) 14.4 (0.67) 3.5 (0.17)
Total no. of
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Total no.
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autopsies
year
Candida Aspergillus
% of mycoses
among total
autopsies Others Unknown
 a Complicated bZygomycetes
% of caes among total mycoses (% of cases among total autopsy)
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cryptococcosis was not remarkably changed (ranging from 0.14% to 0.28%).  
 
 
Until 1989, the predominant causative agent was Candida, followed by 
Aspergillus and then Cryptococcus. Although the rate of candidiasis decreased by 
degrees from 1990, the rate of aspergillosis increased, and surpassed that of candidiasis 
in 1991. Since 1994, the rate of aspergillosis has increased rapidly, and matches an 
increase reported by the National Statistics Center in mycoses as the certified direct 
cause of death (FIG. 2). When the annual figures for causative agents of visceral 
mycoses in 1989, 1999, and 2009 were compared, the predominant causative agent has 
changed from Candida to Aspergillus over the two decades (FIG. 3). 
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FIG. 2 Annual trends of total visceral mycoses reported in autopsy cases and the major causative agents.
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FIG. 3  A comparison of causative agents for visceral mycoses in autopsy cases.   
 
Each agent is reported as a percentage of annual total mycoses during two decades.  
 
TABLE 2 lists the organ distribution of these causative agents. TABLE 2a 
shows the frequency between 1989 and 1994 and reveals that 37.2% of candidiasis was 
observed in the digestive ducts (mouth and tongue 2.2%, esophagus 15.9%, stomach 
11.1%, and intestine 8.0%), 34.7% was observed in the lung and bronchial system, and 
23.3% in the kidney. The frequency of heart infections by Candida was also high at 
13.4%, and high rates of systemic candidiasis (16.7%) and candidemia (13.7%) were 
also observed. For aspergillosis, the most commonly infected organ system comprised 
the lung and bronchia (83.9%); other organs were not involved at a high rate. 
Cryptococcus also infected the lungs and bronchia most frequently (64.0%), followed 
by the brain and meninx (21.5%). Zygomycosis was also observed most commonly in 
the lung and bronchia (69.4%), followed by the liver (9.6%) and kidney (9.1%). Ten 
year later, substantial changes in these distribution trends were seen only in candidiasis 
27.9 
44.6 
5.4 
3.9 
0.3 
14.4 
3.5 
Aspergillus
42.3 
30.1 
5.4 
3.6 
0.2 
13.0 
5.1 
29.0 
43.5 
4.5 
2.3 0.0 
16.7 
3.9 
Candida Aspergillis
Cryptococcus Zygomycetes
others Unknown
Complicated
1999 (n=1,243)
Candida
Aspergillus
1989 (n=1,672) 2009 (n=648)
Candida Candida
Aspergillus
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(TABLE 2b). In particular, the rate of Candida infections other than candidemia 
decreased by a range of between a quarter and a half. Changes in the organ distribution 
of other causative agents were not remarkable.  
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Infection type 
or organ
% of infections  caused  by :
Candida Aspergillus Cryptococcus Zygomycetes
(N=2,172) (N=1,967) (N=289) (N=209)
Total 100.0 100.0 100.0 100.0 
Systemic 16.7 8.6 13.5 9.6 
Fungemia 13.7 4.3 4.8 5.3 
Brain + meninx 4.1 3.3 21.5 5.3 
Mouth + tongue 2.2 0.3 0.0 0.0 
Esophagus 15.9 1.3 0.7 0.5 
Stomach 11.1 2.9 0.3 7.2 
Intestine 8.0 2.6 0.0 4.8 
Liver 8.1 3.6 3.5 9.6 
Larynx + pharynx 1.2 0.3 0.0 0.0 
Lung + bronchia 34.7 83.9 64.0 69.4 
Heart 13.4 7.4 3.8 7.7 
Kidney 23.3 7.3 9.7 9.1 
Bladder 3.5 0.5 0.0 0.0 
Thyroid 3.5 3.5 2.4 3.3 
Spleen 3.7 2.2 6.2 6.2 
TABLE 2
a) Distribution of causative agents of mycoses by organ; data from 1989 to 1994
Infection type 
or organ
% of infections  caused  by :
Candida Aspergillus Cryptococcus Zygomycetes
(N=1,675) (N=2,677) (N=336) (N=201)
Total 100.0 100.0 100.0 100.0 
Systemic 8.2 5.9 12.2 17.9 
Fungemia 13.5 3.3 4.8 8.5 
Brain + meninx 2.0 1.9 19.3 7.0 
Mouth + tongue 2.9 0.2 0.3 0.0 
Esophagus 17.7 0.6 0.9 1.0 
Stomach 8.7 1.8 0.9 4.5 
Intestine 5.5 1.2 1.5 6.5 
Liver 3.7 1.3 6.5 7.0 
Larynx + pharynx 0.8 0.1 1.5 0.0 
Lung + bronchia 25.6 74.9 55.4 49.3 
Heart 7.9 5.0 1.8 9.5 
Kidney 10.4 3.4 6.3 7.0 
Bladder 2.4 0.1 0.0 1.0 
Thyroid 1.1 1.2 3.0 1.5 
Spleen 1.6 0.6 4.5 2.0 
b) Distribution of causative agents of mycoses by organ; data from 2000 to 2005
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TABLE 3.  Organ distribution data categorized by underlying diseases 
 
 
aData were taken from autopsy cases of 1989, 1990, 1991, and 1993. 
bAML, acute myeloid leukemia; cCML, chronic myeloid leukemia; dALL, acute lymphatic leukemia; eCLL, chronic 
lymphatic leukemia; fMoL, monocystic leukemia; gMDS, myeloldysplastic syndrome, hATL, adult T-cell leukemia;  
iother leukemia: includes other leukemia and non-specified leukemia; jDIC, disseminated intravascular coagulation 
syndrome; kPurpura, idiopathic thrombocytopenic purpura or thrombotic thrombocytopenic purpura. lData were taken 
from 2000, 2002-2004, 2007, and 2009.  
 
In a more detailed analysis of mycoses in the underlying diseases, I compared 
the rate of mycoses in autopsy cases of solid cancer patients with that of patients with 
Disease type Diagnosis pts totala mycosis % Diagnosis pts totall mycosis %
Lung 15,340 369 2.4 Lung 13,724 368 2.7
Stomach 12,719 227 1.8 Stomach 10,004 148 1.5
Liver 13,985 167 1.2 Liver 10,307 164 1.6
Pancreas 5,046 100 2.0 Pancreas 4,463 105 2.4
Colon 7,140 82 1.1 Colon 6,934 84 1.2
Esophagus 3,124 58 1.9 Esophagus 2,846 66 2.3
Solid cancer Gall bladder 3,478 67 1.9 Gall bladder 2,101 32 1.5
Breast 2,274 37 1.6 Breast 1,634 34 2.1
Uterus 2,068 40 1.9 Uterus 1,388 25 1.8
Prostate 3,278 29 0.9 Prostate 5,279 35 0.7
Ovary 1,248 32 2.6 Ovary 945 40 4.2
Kidney 2,110 38 1.8 Kidney 2,158 22 1.0
Bladder 1,590 41 2.6 Bladder 1,610 29 1.8
Brain 1,824 37 2.0 Brain 1,205 27 2.2
Thyroid 3,005 15 0.5 Thyroid 2,695 4 0.1
Pharynx 752 20 2.7 Pharynx 641 13 2.0
total 78,981 1,359 1.7 total 67,934 1,196 1.8
AMLb 1,753 620 35.4 AML 1,883 590 31.3
CMLc 424 185 43.6 CML 454 127 28.0
ALLd 745 319 42.8 ALL 533 264 49.5
CLLe 119 17 14.3 CLL 126 18 14.3
MoLf 278 49 17.6 MoL 135 30 22.2
MDSg 473 105 22.2 MDS 974 192 19.7
ATLh 535 116 21.7 ATL 540 121 22.4
other leukemiai 1,740 95 5.5 other leukemia 899 101 8.3
(Leukemia and MDS) 6,067 1,506 24.8 (Leukemia and MDS) 5,544 1,443 26.0
Malignant lymphoma 4,649 487 10.5 Malignant lymphoma 5,782 505 8.7
Multiple myeloma 1,834 170 9.3 Multiple myeloma 1,577 90 5.7
Aplastic anemia 388 103 26.5 Aplastic anemia 1,613 95 5.9
DICj 1,761 18 1.0 DIC 5,549 54 1.0
Purpurak 130 12 9.2 Purprua 226 23 10.2
Immune dis. 52 10 19.2 Immune dis. 483 44 9.1
AIDS 109 25 22.9 AIDS 208 61 29.3
(Total for other
hematopoietic system
diseases)
8,923 825 9.2
(Total for other
hematopoietic system
diseases)
15,438 872 5.6
Total 14,990 2,331 15.6 Total 20,982 2,315 11.0
Blood and hematopoietic
system diseases
b) Mycoses in 6 years total of two categories
between 2000-2009
a) Mycoses in 4 years total of two categories
between 1989-1993
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blood and hematopoietic system diseases to understand which patients were at greater 
risk of dying from mycoses after contracting an underlying disease. Between 1989 and 
1993, in autopsied patients with leukemia or myelodysplastic syndrome (MDS), 24.8% 
had visceral mycoses, whereas in patients with hematopoietic system diseases other 
than leukemia the figure was 9.2%, and in patients with solid cancers was 1.7%. 
Therefore, the combined frequency rate of 15.6% for the blood and hematopoietic 
system diseases, including leukemia, malignant lymphoma, aplastic anemia, multiple 
myeloma, etc., was 9.1 times the rate of 1.7% for solid cancers. If the comparison is 
narrowed down to autopsied leukemia and MDS patients, the frequency of mycosis was 
more than 14.6 times higher than in solid-cancer patients (24.8 and 1.7%, respectively). 
A breakdown of the frequency of mycosis within each of these major underlying 
diseases over the same period shows that visceral mycoses were observed in solid 
cancers more frequently in pharyngeal cancer (2.7%), ovarian cancer (2.6%), bladder 
cancer (2.6%), and lung cancer (2.4%), and were observed in blood and hematopoietic 
system diseases, more frequently in chronic myeloid leukemia (CML) (43.6%), acute 
lymphatic leukemia (ALL) (42.8%) and acute myeloid leukemia (AML) (35.4%) 
(TABLE 3a). In the data from 2000 to 2009, almost the same tendency can be observed 
(TABLE 3b). Visceral mycoses in autopsied leukemia and MDS patients accounted for 
26.0%, followed by patients with other blood and hematopoietic system diseases other 
than leukemia at 5.6%, and by patients with solid cancers at 1.8%. The combined 
frequency rate for blood and hematopoietic system diseases of 11.0% is 6.5 times higher 
than that for solid cancers of 1.8%. In this period, mycoses were observed within the 
autopsied solid cancer patients most frequently in those with ovarian cancer (4.2%), 
lung cancer (2.7%), pancreatic cancer (2.4%), and esophageal cancer (2.3%), and within 
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patients with blood and hematopoietic system diseases most frequently in those with 
ALL (49.5%), AML (31.3%), AIDS (29.3%), and CML (28.0%).  
In both periods, the number of patients with solid cancer that were autopsied 
(in each 78,981 and 67,934) in much greater than those with leukemia and MDS (in 
each 6,067 and 5,544), but an examination of the rate of mycoses in the two underlying 
diseases shows that mycoses may occur with a much higher frequency in patients with 
leukemia or MDS than in those with solid cancers (TABLE 3a, b).  
 
TABLE 4. Causative agents of mycoses in the major underlying diseases compared for the 
periods 1989 to 1994 and 2000 to 2005  
 
When the causative mycotic agents for the four major underlying diseases, 
1989-1994
n % n % n % n % n %
Candida 397 26.4 713 48.0 178 36.6 64 37.6 3 30.0
Aspergillus 564 37.5 377 25.4 151 31.0 50 29.4 2 20.0
Cryptococcus 25 1.7 90 6.1 19 3.9 13 7.6 2 20.0
Zygomycetes 101 6.7 23 1.5 17 3.5 12 7.1 0 0.0
Other 5 0.3 2 0.1 1 0.2 0 0.0 0 0.0
Unknown 296 19.7 246 16.6 102 20.9 23 13.5 2 20.0
Complicated 118 7.8 34 2.3 19 3.9 8 4.7 1 10.0
Total 1,506 100.0 1,485 100.0 487 100.0 170 100.0 10 100.0
2000-2005
n % n % n % n % n %
Candida 217 18.2 450 41.6 156 28.8 44 22.6 68 17.9
Aspergillus 634 53.1 402 37.2 259 47.9 108 55.4 211 55.5
Cryptococcus 23 1.9 74 6.8 18 3.3 13 6.7 6 1.6
Zygomycetes 106 8.9 10 0.9 21 3.9 4 2.1 19 5.0
Other 4 0.3 0 0.0 1 0.2 0 0.0 2 0.5
Unknown 144 12.1 127 11.7 58 10.7 17 8.7 56 14.7
Complicated 66 5.5 18 1.7 28 5.2 9 4.6 18 4.7
Total 1,194 100.0 1,081 100.0 541 100.0 195 100.0 380 100.0
Lymphoma Myeloma
Leukemia and
MDS
Organ
transplantation
Leukemia and
MDS
Organ
transplantationSoild cancers Lymphoma Myeloma
Soild cancers
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(leukemia including MDS, solid cancer, lymphoma, and myeloma) and solid-organ 
transplantation cases were compared (TABLE 4), aspergillosis was the most 
predominant causative agent in leukemia and MDS, between 1989 and 1994, followed 
in order by candidiasis, zygomycosis, and cryptococcosis; however, for other three 
underlying diseases, candidiasis was the most frequent disease, followed by 
aspergillosis and cryptococcosis. In contrast, from 2000 to 2005, the predominant 
causative agent in these four major underlying diseases and in organ transplantation was 
aspergillosis followed by candidiasis. Mycoses in organ transplanted patients were 
reported in only 10 cases in the earlier period, but featured in 380 cases in the later 
period. Most systemic or multiorgan mycotic infections caused patients to die within a 
short period, responded poorly to currently available antifungal agents, or required a 
long period of treatment.            
FIG. 4 Increase in the proportion of severe infections within total mycoses.  
       severe infection;      non-severe infection.   
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The frequency of severe mycotic infections has also increased dramatically   
over the 25-year study period, from 6.6% of the total visceral mycosis cases in 1969 to 
71.3% in 1994 (FIG. 4). After 1994, however, the rate of severe infection decreased to 
around 40% over the next 15 years. When the proportions of causative agents for the 
severe mycoses were compared for the years 1989 and 1994, candidiasis (41.2%) was 
found to be the most frequent mycosis, followed by aspergillosis (28.5%), in 1989, but 
aspergillosis (44.5%) surpassed candidiasis (27.6%) in 1994 (FIG. 5). Furthermore, this 
ratio in 1994 was maintained in 2004.  
 
FIG. 5. Comparison of the proportion of causative agents for severe mycoses in 1989, in 1994 
and in 2004. 
 Each agent is reported as a percentage of total mycoses. Severe candidiasis cases decreased but aspergillosis 
cases increased in 1994, a situation that was maintained in 2004. 
 
Analysis of the frequency of severe infections for each causative agent showed 
that 93% of zygomycosis, 83% of cryptococcosis, 78% of aspergillosis, and 56% of 
candidiasis cases were found among the severe cases in 1994. The rate for each agent 
had been almost exactly 50% in 1989 (data not shown). 
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TABLE 5.  Frequencies and rates of the visceral mycoses reported by age a  
a The highest frequency of mycoses was observed for individuals in their 20s, whereas the highest incidence was in 
those in their 60s and 70s in each period. Neonatal babies showed a tendency to suffer from candidiasis due to an 
endogenous pathogen. These data were taken from the data of 1993, 1994, 2003, and 2004.  
 
In comparison of the mycoses rate over 2 years from 1993 to 1994 and that 
from 2003 to 2004, the highest frequency of mycoses by age was observed in patients in 
their 20s, whereas the highest incidence was observed in those in their 60s and 70s. 
Observing the figures over the decade, there was no difference between the period 1993 
to 1994 and 2003 to 2004. Particularly the neonatal babies showed a tendency to suffer 
from candidiasis, which might be caused by endogenous pathogens (TABLE 5).  
There was no remarkable difference between genders in the frequency of 
visceral mycoses in total autopsies as determined from the 1993 and 1994 compiled data. 
There was little difference in candidiasis between males and females (1.21% and 1.31%, 
respectively); cryptococcosis was found at a higher frequency in females than in males 
(0.29% and 0.13%, respectively) in total autopsy cases, whereas aspergillosis was found 
1993+1994
Age
Total no. of 
autopsy cases
Total 
mycoses Candida Aspergillus Cryptococcus Zygomycetes others unknown complicated
cases % cases % cases % cases % cases % cases % cases % cases %
Neonatal babies 1,491 23 1.54 18 1.21 0 0.00 0 0.00 0 0.00 0 0.00 5 0.34 0 0.00
0-9 1,324 40 3.02 17 1.28 12 0.91 0 0.00 2 0.15 0 0.00 7 0.53 2 0.15
10-19 532 52 9.77 14 2.63 25 4.70 0 0.00 4 0.75 0 0.00 6 1.13 3 0.56
20-29 836 84 10.05 36 4.31 34 4.07 2 0.24 5 0.60 0 0.00 6 0.72 1 0.12
30-39 1,203 84 6.98 29 2.41 31 2.58 5 0.42 5 0.42 0 0.00 11 0.91 3 0.25
40-49 3,942 156 3.96 39 0.99 75 1.90 10 0.25 5 0.13 0 0.00 20 0.51 7 0.18
50-59 8,169 312 3.82 105 1.29 120 1.47 14 0.17 10 0.12 0 0.00 47 0.58 14 0.17
60-69 16,385 544 3.32 192 1.17 209 1.28 27 0.16 18 0.11 2 0.01 75 0.46 22 0.13
70-79 15,561 537 3.45 194 1.25 220 1.41 30 0.19 11 0.07 1 0.01 62 0.40 19 0.12
80- 9,567 186 1.94 92 0.96 48 0.50 17 0.18 7 0.07 1 0.01 18 0.19 4 0.04
Total 59,010 2,018 3.42 736 1.25 774 1.31 105 0.18 67 0.11 4 0.01 257 0.44 75 0.13
2003+2004
Age
Total no. of 
autopsy cases
Total 
mycoses Candida Aspergillus Cryptococcus Zygomycetes others unknown complicated
cases % cases % cases % cases % cases % cases % cases % cases %
Neonatal babies 602 5 0.83 3 0.50 0 0.00 0 0.00 0 0.00 0 0.00 2 0.33 0 0.00
0-9 624 20 3.21 13 2.08 3 0.48 0 0.00 1 0.16 0 0.00 3 0.48 0 0.00
10-19 217 13 5.99 5 2.30 3 1.38 0 0.00 2 0.92 0 0.00 2 0.92 1 0.46
20-29 407 25 6.14 5 1.23 17 4.18 0 0.00 0 0.00 0 0.00 2 0.49 1 0.25
30-39 882 33 3.74 12 1.36 13 1.47 1 0.11 1 0.11 0 0.00 6 0.68 0 0.00
40-49 1,729 84 4.86 20 1.16 40 2.31 5 0.29 3 0.17 0 0.00 10 0.58 6 0.35
50-59 5,163 264 5.11 74 1.43 127 2.46 10 0.19 12 0.23 1 0.02 28 0.54 12 0.23
60-69 9,350 398 4.26 124 1.33 177 1.89 21 0.22 18 0.19 1 0.01 40 0.43 17 0.18
70-79 13,304 564 4.24 177 1.33 250 1.88 51 0.38 17 0.13 1 0.01 49 0.37 19 0.14
80- 8,336 276 3.31 91 1.09 119 1.43 20 0.24 6 0.07 0 0.00 37 0.44 3 0.04
Total 40,614 1,682 4.14 524 1.29 749 1.84 108 0.27 60 0.15 3 0.01 179 0.44 59 0.15
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slightly more frequently in males (1.39%) than in females (1.18%). The frequency of 
mycoses in both sexes relative to total autopsies was almost the same (3.4%). Almost 
the same trend was observed in the data compiled in 2003 and 2004 (TABLE 6). 
 
TABLE 6.  The ratio between the sexes of mycoses in total autopsy cases 
 
a M: male, F: female.  There was no remarkable difference between the gender in the data of 1993 and 1994, and of 
2003 and 2004 
 
  
a. 1993+1994
mycoses cases ratio of pathogen (%) rate in total autopsies (%)
Ma Fa M F M F
Candida 453 282 35.4 37.8 1.21 1.31
Aspergillus 520 254 40.7 34.0 1.39 1.18
Cryptococcus 43 62 3.4 8.3 0.11 0.29
Zygomycetes 42 25 3.3 3.3 0.11 0.12
others 13 1 1.0 0.1 0.03 0.00
unknown 162 95 12.7 12.7 0.43 0.44
complicated 46 28 3.6 3.7 0.12 0.13
total 1,279 747 100.0 100.0 3.41 3.47
b. 2003+2004
mycoses cases ratio of pathogen (%) rate in total autopsies (%)
M F M F M F
Candida 327 197 29.5 34.1 1.23 1.38
Aspergillus 516 235 46.6 40.7 1.94 1.65
Cryptococcus 54 54 4.9 9.4 0.20 0.38
Zygomycetes 44 16 4.0 2.8 0.17 0.11
others 2 1 0.2 0.2 0.01 0.01
unknown 129 50 11.7 8.7 0.49 0.35
complicated 35 24 3.2 4.2 0.13 0.17
total 1,107 0 577 100.0 100.0 4.16 4.05
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Discussion 
 
Candidiasis is the most common mycotic disease in Japan, requiring the 
treatment of 74,000 patients (ca. 6,000 males and ca. 68,000 females) who received 
medical treatment in hospitals or clinics in 1993 (106). The most frequently presented 
symptoms were of Candida vaginitis in women in their 20s and 30s; however, very few 
of the visceral-candidiasis patients succumbed to the disease. FIG. 1 shows the 
frequency of mycoses that were certified as a direct cause of death. Total deaths 
increased from 700,000 in 1969 to 1,150,000 in 2009, and mycotic infections also 
increased from 93 cases in 1969 to 939 cases in 2009. This total may well be inaccurate 
because, even if a patient suffers from a mycosis and dies from that mycosis in the 
presence of an underlying disease, the difficulty in making a diagnosis may mean that 
the direct cause of death is certified as being the underlying disease. From 1995, when 
ICD-10 started to be used to ascribe causative agents, Aspergillus came to be a major 
causative agent directly responsible for death. From then until 2009, and despite the 
change in categorizing the causative agents, total mycoses cases have been increasing 
and the involvement of aspergillosis has been increasing explosively. 
This epidemiological and etiological study used the retrospective autopsy data 
that was compiled by the Japanese Society of Pathology gathered from university 
hospitals, public hospitals, and large private hospitals all over Japan. Visceral mycoses 
continued to increase up to 1990, but from 1991 they started to decrease, with 
candidiasis cases in particular tending to decrease after 1989. In contrast, the increase in 
aspergillosis cases up to 1990 remained constant at 1.3% of total autopsy cases from 
1990 to 1994. Groll et al. also reported almost the same trend for the increase of 
aspergillosis in their pathological autopsy data obtained in Frankfurt, Germany (22, 23). 
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The major reason for this turnaround in the data is thought to be the introduction of FLC 
in Japan. FLC treatment has likely decreased the cases of both severe and non-severe 
Candida infections; however, its activity against aspergillosis would be limited (2, 10, 
74). Kujath and Lerch reported their clinical experience in treating Aspergillus 
infections of multiple soft-tissue injuries, which did not improve when treated with FLC 
(300 mg daily for 16 days) (74). Anaissie et al. also reported that one patient with 
pneumonia due to Aspergillus glaucus responded only partially to FLC at 2,000 mg/day 
and that three patients did not respond to high-dose FLC treatment (more than 800 
mg/day) (2). Thus, they concluded that the activity of FLC was limited in severe 
infections by Aspergillus species and other molds.  
In Japan, the introduction of FLC in the middle of 1989 was a kind of turning 
point against candidiasis (18, 29, 75) but not against other severe mycoses such as 
invasive aspergillosis. Although ITC was introduced in 1993, the effect of ITC on 
clinical outcomes is not clear within this surveyed period. When the causative agents for 
1989 and 1994 were compared, we could see that the predominant causative agent for 
severe mycotic infection had shifted from Candida to Aspergillus, and the proportion of 
severe infections among the total mycoses had increased from 6.6% in 1969 to 71.3% in 
1994 (FIG. 4, 5). I surmise that the reasons for this decrease of candidiasis combined 
with an increase of aspergillosis or of other severe mycotic infections might be that (i) 
antifungal-responsive infections were excluded from the case totals, because they had 
become controllable by antifungal drugs such as FLC (launched in the middle of 1989 
in Japan); (ii) empirical therapy was commonly given to prevent immunocompromised 
patients from acquiring primary mycoses; (iii) available antifungal drugs were partially 
efficacious for severe infections; (iv) diagnostic techniques for both candidiasis and 
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aspergillosis were inadequate and not yet fully developed until the end of 1994 (19, 72, 
110, 119); or (v) the number of patients living longer in an immunocompromised state 
increased as a result of developments in chemotherapy, solid organ transplantation, and 
bone marrow transplantation (BMT).  
Until 1994, kidney transplantation was not uncommon, even in Japan, but liver 
transplantation was still rare and BMT was so rare that we could not find the report of 
mycoses after BMT in the reports of pathological autopsy cases up to 1994. Recently, 
the number of solid organ transplantation cases is increasing, and BMT is a common 
procedure in Japan. Similarly, although many AIDS patients have been diagnosed in the 
United States and European countries, AIDS patients were rare in Japan until 1994 (15, 
21, 23). In fact, more recent data shows that more than 20% of patients suffering from 
AIDS have been reported to have mycotic infection as a complication (TABLE 3). Even 
now, cases of severe visceral mycoses are essentially uncontrollable, and especially 
Aspergillus infections were still increasing in 2009 (7, 14, 23, 117). Therefore, there is 
an urgent unmet medical need for drugs that are highly potent against visceral mycoses 
and have efficacy against aspergillosis, azole-resistant Candida strains, or non-albicans 
Candida species, as well as other mycoses.  
With respect to the affected-organ distribution data (TABLE 2), the rate of 
candidemia was higher than that of fungemia from Aspergillus, Cryptococcus, or 
zygomycetes. The increasing use of indwelling intravenous catheters might be one 
major infection route for fungemia, and Candida as an endogenous pathogen infects 
more easily than other pathogens. According to the report of the nosocomial 
bloodstream infections (BSIs) in the US hospitals, of 24,179 patients with BSIs from 
1995 to 2002, 9.0% was caused by Candida (118). Candida BSI was the fourth most 
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common in all BSIs and followed the coagulase negative Staphylococcus, 
Staphylococcus aureus, and enterococci. However, BSIs from other fungal species was 
not reported. Although the causative agents affected organs differently, the lung and 
bronchial system were most frequently involved, regardless of the pathogen species. 
This suggests that the lung and bronchia are at the highest risk of being exposed to not 
only exogenous pathogens, such as Aspergillus, Cryptococcus, or zygomycetes, but also 
to Candida species. Although Candida species are normally found commensally in the 
digestive tract, it is possible for them to be a major causative agent of systemic infection 
in immunocompromised patients and of topical infections in healthy individuals. 
Further, Candida is known to be involved in nosocomial transmission (5), which might 
explain why the lungs and bronchia are found to be the organs predominantly infected 
by Candida. To support this, Candida infections were also observed more commonly 
than those of Aspergillus, Cryptococcus, and zygomycetes species in the esophagus and 
stomach.  
The data from autopsy surveys include patients of antemortem-diagnosed cases 
as well as those recognized by postmortem necropsy. The former cases include those 
not completely cured at the time that death occurred from the underlying disease or the 
mycosis. In Japan, only about 3% of bodies are subjected to pathological autopsy. I 
assume that even if we were able to analyze all patients who died from disease, the 
frequency of mycotic infection would probably not change much statistically. However, 
if I could count all mycosis patients regardless of their good or bad convalescence, the 
rate of mycoses would probably be greatly different from the result that we arrived at in 
this study. This is because most of the data on mycoses obtained at autopsy must be 
biased toward those patients who had died from malignant diseases. Almost all systemic 
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fungal infections, especially those caused by Aspergillus or zygomycetes, in 
immunocompromised patients are refractory to all antifungal agents currently available, 
even though effective drugs do exist for less severe or locally limited infections. I would 
expect, however, that many such patients could be cured of or prevented from 
contracting systemic mycoses with aggressive effective treatments. Despite the 
limitations inherent in individual autopsy data in Japan, they are still worthy of use to 
gain much epidemiological and etiological information. Nevertheless, further 
information could be derived by using newer data, as they become available, and with 
other means of analysis. 
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Part II 
 
In vitro Activity of Isavuconazole against 140 Reference Fungal Strains 
and 165 Clinically Isolated Yeasts from Japan 
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Abstract 
 
In vitro susceptibilities of 140 laboratory reference strains of fungi, including type 
strains, and 165 clinical yeast isolates from Japan towards a CYP51 inhibitor, 
isavuconazole, compared with fluconazole (FLC), itraconazole (ITC), voriconazole 
(VLC) and amphotericin B (AmB) were measured. Broth microdilution methods based 
on Clinical and Laboratory Standards Institute (CLSI) methods were used for yeasts, 
and RPMI-MOPS medium semi-solidified with 0.2% low-melting-point agarose, based 
on CLSI guidelines was used for molds. The range of isavuconazole minimum 
inhibitory concentrations (MICs) was 0.0004–0.21 mg/L for Candida albicans, 
0.0036–0.4 mg/L for Candida glabrata, 0.023–0.058 mg/L for Candida krusei, 
0.0026–0.032 mg/L for Cryptococcus neoformans, 0.1–0.39 mg/L for Aspergillus 
fumigatus and 0.2–0.39 mg/L for Aspergillus terreus. Isavuconazole was as active as 
ITC against the dimorphic true pathogenic fungi, with a range of MICs from <0.0004 
mg/L to 0.0063 mg/L for Blastomyces dermatitidis and Histoplasma capsulatum. It was 
also active against uncommon dematiaceous fungi such as Exophiala spp. and 
Phialophora spp. as well as against dermatophytic species. Isavuconazole showed very 
good in vitro antifungal activity with a broad spectrum, including against FLC-resistant 
Candida spp., Aspergillus spp. and uncommon opportunistic fungal species. No 
cross-resistance was found to isavuconazole amongst FLC-resistant strains. Against 
Fusarium, Pseudallescheria, Scedosporium, and zygomycetes species, isavuconazole 
showed a limited or partial activity, and these fungi species are probably intrinsically 
resistant to azoles.  
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The following text in the abstract has been omitted pending regulatory approval of 
Isavuconazole. 
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Introduction 
 
Despite advances in antifungal therapy, fungal infections remain a major cause 
of morbidity and mortality in immunocompromised patients, with fatality rates of 
50–100% in such patients (85). Candida and Aspergillus are the major opportunistic 
pathogens and are the predominant causative agents of mortality in patients with 
hematological malignancies (76). Candida albicans is the leading cause of neonatal 
fungal sepsis, but non-albicans Candida species have become more frequent causative 
organisms (82).  
AmB has long been regarded as the gold standard for the treatment of invasive 
and disseminated fungal infections in critically ill patients.  However, the drug has 
serious safety concerns associated with renal toxicity, hypokalemia, and 
hypomagnesemia (111), and recent case reports documented clinical failure with this 
agent against infections caused by non-albicans Candida such as C. rugosa (9), C. 
lusitaniae (84) and C. glabrata (73). Azoles are potent compounds; however, some of 
the drugs on the market have problems such as a narrow spectrum and resistance to FLC, 
or specific issues, such as the variability in the bioavailability of posaconazole (112) 
and the drug-drug interactions of ITC (11).  The echinocandins have emerged as useful 
therapeutic options for invasive candidiasis but case reports describing reduced in vitro 
activity and clinical failure of caspofungin against C. albicans, C. glabrata, and C. 
krusei have appeared (25, 26, 71, 86).  There exists an eminent need for more potent 
and safer antifungal compounds available for both parenteral and oral administration. 
Therefore, the target enzyme of the ergosterol synthesis pathway has been chosen to 
make a novel antifungal agent. The enzyme of CYP51 (=ERG11) is a lanosterol C14 
α-demethylase that converts lanosterol into ergosterol, and plays an important role in 
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ergosterol synthesis. Azole compounds are well-known validated inhibitors of CYP51. 
RO0094815 was screened from hundreds of triazole derivatives synthesized, and 
showed a potent inhibitory activity against fungal pathogens in vitro and in vivo models 
(121). RO0094815 was named isavuconazole (81). As the isavuconazole is poorly 
soluble in water, that compound was specially designed as a water-soluble prodrug 
derivative as isavuconazo-lium (-nium) for both oral and intravenous administration 
available (91).  
I show here that isavuconazole has a broad spectrum of action in vitro. The 
results of the comparison of the antifungal activity data of four azoles and AmB against 
reference strains suggest that using broth microdilution methods and spectrophotometry 
to turbidimetrically measure growth are very helpful when performing in vitro 
antifungal susceptibility tests. 
At present, this potent antifungal drug that was developed as a result of this 
research is now in clinical phase III studies in the US. Some studies have been 
completed and the latest result of one study has met the primary endpoint.  
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Materials and Methods 
Antifungal drugs 
Isavuconazole and VRC were synthesized at the Nippon Roche Research 
Center (now Kamakura Research Laboratories, Chugai Pharmaceutical Co., Kanagawa, 
Japan), and ITC and FLC were prepared from the commercial products Itrizole® 
(Janssen Pharmaceutical K.K., Tokyo, Japan) and Diflucan® (Pfizer Japan Inc., Tokyo, 
Japan). AmB was purchased from Sigma Chemical Co. (St Louis, MO). All drugs were 
dissolved at a concentration of 20 mg/mL with dimethyl sulfoxide (DMSO) and were 
stored at temperatures below −20ºC. 
 
Fungal strains 
In this study, 140 laboratory reference strains of fungi and 165 yeast clinical 
isolates from Japan were examined. Strains purchased from the American Type Culture 
Collection (ATCC, Manassas, VA) included the Clinical and Laboratory Standards 
Institute (CLSI) quality control (QC) strains Candida parapsilosis ATCC 22019 and C. 
krusei ATCC 6258 as well as reference strains C. albicans ATCC 90028, C. albicans 
ATCC 24433, C. parapsilosis ATCC 90018, and C. tropicalis ATCC 750. Strains 
designated NCPF were purchased from the National Collection of Pathogenic Fungi 
(Bristol, UK). Strains purchased from the Institute for Fermentation Osaka were 
designated IFO and are deposited in the NITE Biological Resource Center (Tokyo, 
Japan). Strains purchased from the Institute of Applied Microbiology (University of 
Tokyo, Japan) were designated IAM and are deposited in the RIKEN BioResource 
Center (Saitama, Japan). Other clinical isolates were from clinical specimens of sputum, 
blood, stool, urine, and vaginal discharge collected in Japan between 1991 and 1998. 
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In vitro antifungal susceptibility 
Fungal strains used in this report were maintained as frozen stock cultures at 
−80ºC. Subcultures for most yeasts were made on Sabouraud dextrose agar or YPD agar 
(1% yeast extract, 2% peptone, 2% dextrose, and 2% agar); potato dextrose agar was 
used for common molds and MYSA (1% malt extract, 0.1% yeast extract, 0.1% soytone, 
1% dextrose and 2% agar) was used for uncommon molds such as zygomycete species 
and dematiaceous fungi. Czapek yeast extract agar supplemented with 20% sucrose (69) 
was used for collecting conidia effectively from Aspergillus spp. and Penicillium spp. 
For dimorphic true pathogenic fungi such as Histoplasma capsulatum and 
Blastomyces dermatitidis (Ajellomyces dermatitidis), ATCC Culture Medium 906 Pine 
and Drouhet’s Histoplasma yeast-phase medium were used for the subculture. The 
inocula of yeast-phase conidia were prepared as suspension of 1–3×106 conidia/mL with 
saline. The inocula of filamentous fungi (molds) were prepared as conidial suspensions 
of 1–3×106 conidia/mL with BSG80 comprised of 0.85% NaCl, 0.03% KH2PO4, 0.06% 
Na2HPO4, 0.1% Tween 80 and 0.01% gelatin (Difco Laboratories, Detroit, MI). For 
antifungal susceptibility testing, MICs were determined using both a spectrophotometer 
and a reading mirror by the modified broth microdilution methods outlined by the CLSI 
(88, 89). Modifications were as follows: first, the drugs were diluted in DMSO from 
100% to 10% with sterile distilled water instead of the medium to avoid precipitation of 
hydrophobic drugs owing to the salts in the medium; second, the RPMI-MOPS medium, 
semi-solidified by adding 0.2% low-melting-point agarose (LMPA) (Gibco BRL, Grand 
Island, NY) was used for the filamentous fungi (molds) to avoid precipitation of conidia 
and to reduce aerobic growth on the medium surface; and third, 96-well flat-bottomed 
microtitre plates were used, to facilitate the use of spectrophotometry to measure the 
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optical density (OD) of molds. Before the susceptibility test, QC strains of yeasts were 
used to confirm that there were no differences between the MICs determined using a 
semi-solid medium and an ordinary liquid medium. Brain–heart infusion medium 
(Difco) supplemented with 0.1% cysteine and 1.0% dextrose, solidified with 0.2% 
LMPA, was used for the examinations of the dimorphic true pathogenic fungi.  
Drugs serially diluted two-fold with 100% DMSO (from 20 mg/mL to 0.04 
mg/L) were diluted ten-fold with sterile distilled water (see above) in microtitre plates 
with a U-shaped well (Falcon, Lincoln Park, NJ). Aliquots (20 µL) of the drug solutions 
were transferred to flat-bottomed 96-well microtitre plates (Falcon) and 80 µL of 
conidia-free medium and 100 µL of 2× inoculum suspension were added. The inoculum 
sizes for common yeast strains were from 1 to 3×103 conidia/mL, and for the molds and 
dimorphic fungi strains were from 1 to 3×104 conidia/mL at the final concentration. The 
final concentration of drug ranged from 0.0004 mg/L to 200 (or 100) mg/L. Before 
incubation, well-mixed media in microtitre plates for the molds were refrigerated for 5 
min to solidify the medium and were then incubated at 35ºC for a suitable period until 
the OD of the control wells was >0.15 for each species. The incubation period was 
typically 1–2 days for fast-growing species and 6–11 days for slow-growing species 
such as Malassezia, dermatophytes, dematiaceous fungi, and dimorphic true pathogenic 
fungi. The MIC endpoint of AmB was defined as the lowest concentration that 
prevented any discernible growth (score 0) for yeasts and molds. Before measuring the 
yeasts, plates containing liquid media were agitated by a plate agitator. The MIC 
endpoint of azoles was defined as the calculated concentration of drug that produced a 
50% reduction of turbidity (score 2) compared with that of the drug-free control. For 
molds, the MICs of ITC, VRC, and isavuconazole were determined from the lowest 
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drug concentration that prevented any discernible growth (score 0), and that of FLC was 
determined by the calculated concentration of drug that produced 80% reduction of 
turbidity (score 1) by spectrophotometry at an OD of 600 nm, with the exception of the 
dermatophytes. For the dermatophyte species, the MICs of all azoles tested were 
determined only from the calculated concentration of drug that produced an 80% 
reduction of turbidity (score 1) measured by spectrophotometry. The MICs of azoles 
against Fusarium, Pseudallescheria, Scedosporium and zygomycete strains were 
determined using the two endpoints (score 0, 100% growth inhibition; and score 1, 80% 
growth inhibition) and that of FLC was determined using one endpoint (score 1). For 
calculation of the geometric mean, a MIC of ≤0.0004 mg/L was considered to be 0.0004 
mg/L and, similarly, a MIC of ≥100 mg/L or ≥200 mg/L was 100 mg/L or 200 mg/L, 
respectively.  
The interpretive breakpoints of azoles have been defined  (20, 24, 89) as 
follows: for FLC, strains with a MIC ≤8 mg/L are considered susceptible and those with 
a MIC ≥64 mg/L are considered resistant; and for ITC, strains with a MIC ≤0.125 mg/L 
are considered susceptible and those with a MIC ≥1 mg/L are considered resistant. For 
VRC and isavuconazole, those with a MIC ≤1 mg/L are considered susceptible and 
those with a MIC ≥4 mg/L as resistant (96). 
 
The sequence alignment and phylogenetic analysis in the Materials and Methods have 
been omitted pending regulatory approval of Isavuconazole. 
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TABLE 7   
In vitro activity [MIC endpoint a (mg/L)] of isavuconazole and comparator agents against 48 laboratory yeast reference strains by spectrophotometric determination. 
MIC, minimum inhibitory concentration; MIC 50/90, MIC for 50% and 90% of the organisms, respectively; FLC, fluconazole; ITC, itraconazole; VRC, voriconazole; AmB, amphotericin B; GM, geometric mean. 
a MIC endpoint: score 2 (50% inhibitory concentration by spectrophotometry) for FLC, ITC, VRC and isavuconazole; and score 0 (optically clear, i.e. no discernable growth) for AmB. 
b Number of incubation days for MIC measurement. 
 
Species N Days b FLC ITC VRC Isavuconazole AmB 
   Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 
Candida albicans 8 1 0.02-20 0.14 20 0.0005-0.091 0.0022 0.091 0.0007-0.29 0.0027 0.29 0.0004-0.21 0.0022 0.21 0.05-0.2 0.05 0.2 
GM for  C. albicans (mg/L)   0.27   0.004   0.006   0.004   0.08   
Candida glabrata 9 1-2 0.5-67 3.0 35 0.0025-0.29 0.024 0.29 0.009-0.81 0.046 0.62 0.0036-0.40 0.02 0.27 0.1-0.2 0.1 0.2 
GM for  C. glabrata (mg/L)   3.7   0.03   0.06   0.03   0.13   
Candida tropicalis 4 1 0.16-0.36 0.24 0.36 0.004-0.006 0.004 0.1 0.011-0.04 0.012 0.04 0.0049-0.02 0.009 0.02 0.1-0.39 0.2 0.39 
GM for C. tropicalis (mg/L)   0.25   0.005   0.016   0.01   0.23   
Candida krusei 3 1 11-25 12 25 0.0094-0.022 0.017 0.022 0.099-0.12 0.06 0.12 0.023-0.058 0.058 0.058 0.39-0.39 0.39 0.39 
GM for  C. krusei (mg/L)   15   0.02   0.09   0.04   0.39   
Candida parapsilosis 3 2 0.26-1.5 0.65 1.5 0.0011-0.0099 0.0081 0.0099 0.0019-0.024 0.017 0.024 0.0007-0.013 0.011 0.013 0.1-0.2 0.1 0.2 
GM for  C. parapsilosis (mg/L)   0.63   0.0045   0.01   0.0046   0.13   
Candida guilliermondii 2 2 0.7-2.2   0.0093-0.027   0.029-0.037   0.021-0.061   0.1-0.39   
Candida kefyr IFO0586 1 2 0.17   0.004   0.0018   0.0006   0.05   
Candida lusitaniae 2 1 0.074-0.16   0.0011-0.0024   0.0021-0.0042   0.0020-0.0052   0.05-0.1   
GM for all  Candida spp. (mg/L) 32  0.9   0.008   0.018   0.011   0.13   
Cryptococcus neoformans 8 2 0.36-2.6 1.3 2.6 0.0013-0.011 0.0059 0.11 0.005-0.034 0.015 0.034 0.0026-0.032 0.012 0.032 0.025-0.1 0.05 0.1 
GM for  C. neoformans (mg/L)   1.2   0.005   0.015   0.012   0.05   
Malassezia furfur 3 6 1.6-9.9 2.7 9.9 0.053-0.078 0.073 0.078 0.011-0.063 0.023 0.063 0.18-0.81 0.18 0.81 6.3-12.5 6.25 12.5 
GM for  M. furfur (mg/L)   3.5   0.07   0.03   0.33   7.9   
Malassezia pachydermatis 2 7-9 1.8-2.7   <0.0004   0.013-0.02   0.0021-0.0027   0.1   
GM for all  Malassezia spp. 
(mg/L) 5  2.9   0.009   0.021   0.046   1.4   
Trichosporon beigelii 2 3 0.024-0.19   0.0029-0.013   0.0017-0.01   0.005   0.1-0.39   
Trichosporon asahi  IFO10844 1 3 5.4   0.051   0.034   0.31   0.39   
GM for all  Trichosporon spp. 
(mg/L)   3  0.29   0.012   0.008   0.020   0.25   
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TABLE  8 
In vitro activity [MIC endpoint a (mg/L)] of isavuconazole and comparator agents against 57 laboratory mould reference strains by spectrophotometric determination. 
 
MIC, minimum inhibitory concentration; MIC 50/90, MIC for 50% and 90% of the organisms, respectively; FLC, fluconazole; ITC, itraconazole; VRC, voriconazole; AmB, amphotericin B; GM, geometric mean; N/T, not tested. 
a MIC endpoint: score 2 (50% inhibitory concentration by spectrophotometry) for FLC, ITC, VRC and isavuconazole; and score 0 (optically clear, i.e. no discernable growth) for AmB. 
b Number of incubation days for MIC measurement. 
C MIC endpoint of dermatophytes species: score 1 for all azoles and score 0 for AmB. 
Species N Days b FLC ITC VRC Isavuconazole AmB 
   Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 
Aspergillus fumigatus 12 2 45->200 190 >200 0.025-0.1 0.05 0.1 0.1-0.2 0.2 0.2 0.1-0.39 0.2 0.39 0.2-0.39 0.39 0.39 
GM for  A. fumigatus (mg/L)   144   0.047   0.16   0.22   0.34   
Aspergillus  terreus   3 2 >200 >200 >200 0.05-0.1 0.05 0.1 0.39 0.39 0.39 0.2-0.39 0.2 0.39 0.39 0.39 0.39 
GM for  A. terreus (mg/L)   >200   0.06   0.39   0.25   0.39   
Aspergillus  flavus  IAM13835 1 2 200   0.1   0.39   0.78   0.39   
Aspergillus  niger ATCC9642 1 2 200   0.2   1.56   1.56   n.d.   
Aspergillus  oryzae   IAM13881 1 2 >200   0.39   0.78   0.39   n.d.   
GM for all  Aspergillus spp. (mg/L) 18  161   0.063   0.25   0.28   0.35   
Trichophyton mentagrophytes  c  3 7 3.6-22 12 22 0.0004-0.011 0.011 0.011 0.02-0.024 0.021 0.024 0.003-0.038 0.028 0.038 0.39 0.39 0.39 
GM for  T. mentagrophytes (mg/L)   11   0.0036   0.022   0.015   0.39   
Trichophyton  tonsurans  c 3 7 2.2-8.3 3.8 8.3 <0.0004-0.051 0.0014 0.0051 0.011-0.047 0.041 0.047 0.003-0.049 0.017 0.049 0.025-0.2 0.2 0.2 
GM for  T. tonsurans (mg/L)   4.1   0.0014   0.028   0.011   0.1   
Trichophyton  rubrum  c 2 7 0.39-3.1   0.0016-0.0056   0.011   0.011-0.012   0.2   
Epidermophyton floccosum c  1 7 1.1   0.0014   0.0074   0.023   0.05   
Microsporum canis  c 1 6 77   0.047   0.03   0.025   0.39   
Microsporum gypseum  c  IFO8231 1 7 12   0.007   0.023   0.015   0.1   
GM for all  dermatophyte  spp. (mg/L) 11  4.7   0.0033   0.021   0.015   0.17   
Alternaria alternata  1 6 180   0.39   1.56   3.1   0.39   
Alternaria mali IFO8984 1 6 23   0.39   0.78   1.56   0.1   
Aureobasidium pullulans  1 7 7.8   0.013   0.025   0.05   0.1   
Cladosporium trichoides 1 6 25   0.013   0.78   0.39   0.39   
Cladosporium carrionii   1 6 2.9   <0.0004   0.013   0.013   0.78   
Cladosporium  herbarum  IFO4458 1 3 48   0.2   1.56   6.25   0.39   
Exophiala dermatitidis 2 7 22-26   0.05-0.1   0.2-0.39   0.39-1.56   0.2-0.39   
Exophiala jeanselmei 2 6-9 18-20   0.0063-0.05   0.2-0.78   0.2-3.1   0.2-0.39   
Exophiala spinifera  1 7 36   0.013   0.39   0.78   1.56   
Exophiala moniliae 1 7 25   0.0031   0.025   0.05   0.2   
Fonsecaea pedrosoi 1 6 19   0.025   0.2   0.39   3.1   
Fonsecaea compacta 1 9 33   0.1   0.2   0.39   3.1   
Paecilomyces variotii 1 6 >200   0.0031   0.78   3.1   0.05   
Penicillium marneffei 1 6 2.7   0.0031   0.025   0.05   0.39   
Penicillium  oxalicum 1 3 >200   0.2   0.78   0.39   0.2   
Phialophora verrucosa 1 6 11   0.1   0.2   0.2   1.56   
Phialophora  parasitica 1 6 170   >200   0.39   0.78   0.78   
Sporothrix schenckii 3 7 >200 >200 >200 >200 >200 >200 12.5-50 25 50 12.5-25 25 25 0.78-3.1 0.78 3.1 
Blastomyces dermatitidis 3 5-11 0.06-0.71 0.11 0.71 <0.0004-0.0008 <0.0004 0.0008 0.0016-0.0063 0.0063 0.0063 <0.0004-0.0008 <0.0004 0.0008 0.025-0.2 0.05 0.2 
Histoplasma capsulatum 3 5-7 0.55-1.2 0.77 1.2 <0.0004 <0.0004 <0.0004 0.0063-0.025 0.0063 0.025 0.0031-0.0063 0.0063 0.0063 0.013-0.05 0.05 0.05 
GM for all  dimorphic, true pathogens  
(mg/L) 
6  0.37   0.0004   0.0063   0.0016   0.045   
 
 
 
44 
 
TABLE 9 
In vitro activity [MIC endpoint a (mg/L)] of isavuconazole and comparator agents against Fusarium, Scedosporium and zygomycetes.  
Species N Days b FLC ITC VRC Isavuconazole AmB 
   GM score 1(range) GM score 1 (range) GM score 0 (range) GM score 1(range) GM score 0 (range) GM score 1(range) GM score 0 (range) GM score 0 (range) 
Fusarium solani 6 2 >200 (>200) 117 (59->200) >200 (>200) 2.1 (1.2-2.9) 8.8 (3.1-25) 13 (5.4-18) 71 (25->200) 0.68 (0.39-1.56) 
Fusarium moniliforme 2 2 (>200) (0.69-27) (>200) (0.45-0.5) (3.1-6.25) (1.2-2.8) (3.1-6.25) (1.56-3.1) 
Fusarium oxysporum IFM41530 1 2 (>200) (>200) (>200) (1.3) (6.25) (2.3) (12.5) (1.56) 
All  Fusarium spp. 9  >200 55 >200 1.4 7.3 6.8 32 0.9 
Pseudallescheria boydii 
(Sedosporium apiospermum) 3 2-6 15 (7.8-27) 0.26 (0.16-0.6) 5.0 (0.39->200) 0.10 (0.052-0.19) 0.39 (0.2-0.78) 0.29 (0.12-0.77) 2.5 (1.56-3.1) 40 (1.56->200) 
Sedosporium prolificans 3 2 >200 (>200) >200 (>200) >200 (>200) 6.6 (5.5-8.7) 50 (50) 6.9 (5.5-10) >200 (>200) >200 (200->200) 
All  Sedosporium spp. 6  100 7.2 32 0.8 4.4 1.4 22 63 
Absidia corymbifera 4 1-2 >200 (>200) 0.056 (0.021-0.086) 0.14 (0.1-0.2) 8.4 (11-28) 30 (12.5-50) 1.2 (0.2-2.1) 1.9 (0.78-3.1) 0.025 (0.025) 
Absidia hyalopsora IFO8084 1 2 (>100) (0.048) (0.1) (2.7) (12.5) (0.18) (0.78) N/T 
Cunninghamella bertholletiae 2 2 (>100) (0.15-0.33) (0.2-0.78) (10-11) (12.5-25) (5.9) (>100) N/T 
Mucor circinelloides IFO4554 1 1 (>200) (0.2) (0.39) (5.5) (12.5) (1.9) (3.1) (0.05) 
Mucor rouxianus IFO5773 1 2 (>200) (>200) (>200) (>200) (>200) (>200) (>200) (0.05) 
Mucor ramosissimus ATCC28933 1 3 (>100) (0.11) (0.2) (13) (50) (2.5) (6.25) N/T 
Rhizomucor pusillus 3 1-2 153 (90->200) 0.04 (0.012-0.33) 0.2 (0.1-0.78) 4.1 (2.7-9.2) 21 (12.5-25) 0.68 (0.24-4.3) 3.1 (1.56-6.25) 0.04 (0.025-0.05) 
Rhizopus oryzae 4 1-2 >200 (>200) 0.33 (0.083-2.2) 1.56 (0.39-100) 6.2 (2.7-12) 21 (6.25-50) 0.92 (0.33-2.9) 3.1 (1.56-12.5) 0.07 (0.05-0.1) 
Rhizopus microsporus 3 2 >100 (>100) 0.27 (0.19-0.33) 0.62 (0.39-0.78) 5.7 (5.3-6.0) 12.5 (12.5) 0.64 (0.59-0.69) 2.0 (1.56-3.13) N/T 
All  zygomycete  species 20  >100 0.18 0.52 8.4 22 1.2 4.4 0.05 
MIC, minimum inhibitory concentration; FLC, fluconazole; ITC, itraconazole; VRC, voriconazole; AmB, amphotericin B; GM, geometric mean; N/T, not tested. 
a MIC endpoint: score 1(80% inhibitory concentration by spectrophotometry) for FLC; score 1/score 0 (optically clear, i.e. no discernable growth) for ITC, VRC, isavuconazole; and score 0 for AmB. 
b Number of incubation days for MIC measurement. 
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TABLE 10  
In vitro activity [MIC endpoint a (mg/L)] of isavuconazole and comparator agents against 165 clinical isolates from Japan 
 
Species N FLC   ITC   VRC   Isavuconazole   AmB   
  GM (range) MIC50 MIC90 GM (range) MIC50 MIC90 GM (range) MIC50 MIC90 GM (range) MIC50 MIC90 GM (range) MIC50 MIC90 
Candida albicans 33 0.054 0.045 0.15 0.0009 0.001 0.0022 0.0010 0.001 0.0025 0.0007 0.0007 0.0013 0.032 0.05 0.05 
(0.018-0.17) (<0.0004-0.0029) (<0.0004-0.0032) (<0.0004-0.0026) (0.0031-0.39) 
Candida glabrata 25 0.97 0.64 3.4 0.0056 0.005 0.019 0.010 0.0076 0.043 0.0055 0.0039 0.02 0.057 0.05 0.1 (0.093-63) (0.0013-0.19) (0.0016-1.1) (0.0011-0.64) (0.0063-0.10) 
Candida tropicalis 24 0.18 0.20 0.48 0.0027 0.004 0.0095 0.0082 0.011 0.017 0.0030 0.0046 0.008 0.069 0.05 0.2 
(0.04-0.91) (<0.0004-0.012) (<0.0004-0.049) (<0.0004-0.0094) (0.025-0.2) 
Candida guilliermondii 15 1.54 1.5 2.4 0.044 0.042 0.14 0.025 0.031 0.046 0.042 0.051 0.11 0.057 0.05 0.39 
(0.65-2.4) (0.0083-0.15) (0.0056-0.062) (0.0069-0.18) (0.025-0.39) 
Candida krusei 10 6.2 5.5 8.8 0.0042 0.0041 0.0079 0.019 0.016 0.03 0.006 0.0041 0.011 0.13 0.1 0.2 (3.7-9.4) (0.0025-0.008) (0.012-0.04) (0.032-0.015) (0.1-0.2) 
Candida parapsilosis 17 
0.22 
0.23 0.61 
0.0019 
0.0019 0.0059 
0.0026 
0.0035 0.015 
0.0013 
0.0015 0.011 
0.085 
0.1 0.2 (0.077-1.1) (0.00042-0.0088) (0.00054-0.018) (<0.0004-0.017) (0.05-0.2) 
Candida lusitaniae 17 
0.069 
0.076 0.15 
0.0008 
0.0006 0.0021 
0.0009 
0.0012 0.0021 
0.0008 
0.00059 0.0024 
0.016 
0.013 0.025 (0.016-0.16) (<0.0004-0.0034) (<0.0004-0.0023) (<0.0004-0.0025) (0.0063-0.025) 
Candida lypolitica 8 
6.2 
7.0 11 
0.005 
0.0056 0.07 
0.048 
0.049 0.074 
0.011 
0.049 0.074 
0.24 
0.2 0.39 (1.4-11) (<0.0004-0.07) (0.032-0.074) (0.032-0.074) (0.1-0.39) 
Trichosporon beigelii 2 0.35   0.014   0.004   0.009   0.14   (0.3-0.42) (0.0095-0.02) (0.0028-0.0055) (0.0031-0.026) (0.1-0.2) 
Cryptococcus 
neoformans 14 
1.5 
1.7 2.3 
0.0027 
0.0033 0.005 
0.0074 
0.0077 0.012 
0.0039 
0.0053 0.0086 
0.012 
0.013 0.025 (0.42-2.6) (<0.0004-0.0052) (0.0021-0.014) (0.0009-0.011) (0.0063-0.025) 
 
MIC, minimum inhibitory concentration; MIC 50/90, MIC for 50% and 90% of the organisms, respectively; FLC, fluconazole; ITC, itraconazole; VRC, voriconazole; AmB, amphotericin B; GM, geometric mean. 
a MIC endpoint: score 2 (50% inhibitory concentration by spectrophotometry) for FLC, ITC, VRC and isavuconazole; and score 0 (optically clear, i.e. no discernable growth) for AmB. 
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Results 
 
Isavuconazole was tested against 140 laboratory strains of fungi and 165 
contemporary clinical yeast isolates from Japan. TABLE 7 shows the activity against 48 
yeasts, including representative strains of C. albicans, non-albicans Candida spp., and 
Cryptococcus neoformans. The activity of isavuconazole was more potent in vitro than 
that of FLC or AmB against all species and was, for the most part, comparable with that 
of ITC and VRC. The respective geometric means of the MICs (mg/L) for 
isavuconazole, FLC, ITC, VRC and AmB for each species were as follows: 0.004, 0.27, 
0.004, 0.006, and 0.08 for C. albicans; 0.03, 3.7, 0.03, 0.06, and 0.13 for C. glabrata; 
0.04, 15, 0.02, 0.09, and 0.39 for C. krusei; 0.01, 0.25, 0.005, 0.016, and 0.23 for C. 
tropicalis; 0.012, 1.2, 0.005, 0.015, and 0.05 for C. neoformans; and 0.33, 3.5, 0.07, 
0.03, and 7.9 for Malassezia furfur. For Candida spp., isavuconazole showed lower in 
vitro activity than ITC and greater activity than VRC, but all these new triazoles showed 
more potent activity than FLC. For C. neoformans, the new triazoles showed similar 
activity. M. furfur showed resistance to AmB, whereas VRC was the most potent azole, 
followed by ITC and isavuconazole. As shown in TABLE 8, isavuconazole was also 
active against Aspergillus spp. and dermatophyte species. The respective geometric 
means of the MICs (mg/L) for isavuconazole, FLC, ITC, VRC and AmB were as 
follows: all Aspergillus spp., 0.28, 161, 0.063, 0.25, and 0.35 (Aspergillus fumigatus 
0.22, 144, 0.047, 0.16, and 0.34); and dermatophyte species, 0.015, 4.7, 0.0033, 0.021, 
and 0.17. Trichophyton mentagrophytes, Microsporum canis, and Microsporum 
gypseum showed rather high MIC values for FLC. However, the MICs of the newer 
triazoles were lower. Isavuconazole was also active against uncommon opportunistic 
fungi and dimorphic pathogens. Against Sporothrix schenckii all four triazoles showed 
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low activity, but AmB showed improved in vitro activity. Furthermore, isavuconazole 
was more potent in vitro than FLC or AmB and was as active as ITC against dimorphic 
pathogens, B. dermatitidis (A. dermatitidis) and H. capsulatum, with MIC values <0.01 
mg/L.  
The activity of isavuconazole against Fusarium, Scedosporium, and 
zygomycete species is shown in TABLE 9. For these species, the MIC endpoints of 
score 0 (100% growth inhibition) and score 1 (80% growth inhibition) were determined 
according to the criteria of Guinea et al. (24). Against Fusarium spp. and Scedosporium 
prolificans, ITC was less active; however, isavuconazole showed limited activity 
against Fusarium moniliforme and Fusarium oxysporum with higher activity than ITC. 
VRC had stronger activity than isavuconazole against Fusarium solani. Isavuconazole, 
ITC, and VRC showed activity against Pseudallescheria boydii (Scedosporium 
apiospermum). Using MICs of the azoles against all of the zygomycete species tested, 
the respective geometric means of MICs (score 1/score 0) (mg/L) for isavuconazole, 
ITC, and VRC were determined to be 1.2/4.4, 0.18/0.52, and 8.4/22, respectively. The 
MIC values of isavuconazole were lower than those of VRC, but ITC presented the 
lowest values in vitro. Mucor rouxianus was not susceptible to any of the four triazoles 
but was susceptible to AmB and showed MICs (score 1/score 0) (mg/L) for 
isavuconazole, ITC, VRC, and AmB of >200/>200, >200/>200, >200/>200 and 0.5, 
respectively. The susceptibility of 165 clinically isolated yeasts in Japan to the four 
azoles and AmB was also examined. Isavuconazole was more potent in vitro compared 
with FLC in all clinical isolates of Candida spp., Trichosporon beigelii, and C. 
neoformans examined (TABLE 10). Comparing the activities of the azoles by MIC90 
(MIC for 90% of the organisms) against clinical isolates, isavuconazole showed no 
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cross-resistance to FLC and showed potency comparable with ITC and VRC. 
Isavuconazole was the most potent against C. albicans and C. tropicalis; VRC was the 
most potent against Candida guilliermondii and T. beigelii; and ITC was the most 
potent against C. krusei, C. parapsilosis, and C. neoformans. As the sensitivity for VCZ 
and isavuconazole was defined in the ‘In vitro antifungal susceptibility’ part of 
Materials and Methods, a MIC value of ≤1 mg/L was considered susceptible and that 
with a MIC ≥4 mg/L as resistant. A partially sensitive was defined between 1 and 4 
mg/L, in this report. Isavuconazole-insensitive or -partially sensitive species were 
regarded as isavuconazole ‘resistant’ species. 
 
The text on the mechanism of resistance and FIGURES in the Results have been 
omitted pending regulatory approval of Isavuconazole. 
  
 
 
49 
 
Discussion 
 
Modified CLSI M27-A2 and CLSI M38-A procedures (88, 89) were applied in 
this study. MICs were measured by OD measurement as well as visual assessment. In 
the antimicrobial susceptibility tests, the test agent used was prepared in the Japanese 
style of two-fold serial dilutions from 100 mg/L, though the dilution style of the USA 
and Europe (a descending dilution from 128 mg/L or 64 mg/L) has recently become 
more common. As MIC values were to be calculated from OD values using 
spectrophotometry instead of visual endpoints, any concentration of drug can be used 
for the first well. Therefore, the MIC values found with our procedure might be slightly 
different when using the original CLSI method. The incubation period was set to attain 
a minimum OD of 0.15 in control wells. Under this condition for the yeast susceptibility 
test, the MIC endpoint used (measured spectrophotometrically) was the lowest 
concentration giving 50% growth inhibition (score 2). The QC strains provided MICs in 
almost the same range as, or a little lower than, the values for azoles suggested in CLSI 
M27-A2 (89). My data with investigated drugs were in the same range of MIC values as 
those reported by Illnait-Zaragozi et al. (30) for C. neoformans. Regarding the yeasts, 
the azole-resistant strain C. albicans NCPF 3303 showed MICs for FLC, ITC, VRC, 
isavuconazole and AmB of 20, 0.091, 0.29, 0.21, and 0.1 mg/L, respectively (28). 
According to CLSI interpretive guidelines (89), this strain was susceptible-dose 
dependent (S-DD; 16–32 mg/L) to FLC and was susceptible to all other azoles. All 
three C. krusei strains, including the QC strain, were S-DD (12–25 mg/L) to FLC but 
susceptible to other antifungals (ITC 0.0094–0.017 mg/L, VRC 0.0099–0.12 mg/L, 
isavuconazole 0.023–0.058 mg/L, and AmB 0.39 mg/L). Semi-solid medium was used 
to study mold and dimorphic pathogenic fungi to avoid conidial precipitation and 
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growth on the medium surface. The 80% inhibitory concentration values were 
determined by spectrophotometry and thus completely excluded experimenter 
subjectivity. Since it is difficult to read the OD of wells covered with growing aerobic 
mycelia, we concluded that semi-solidified media were preferable to determine the 
MICs of the molds. The semi-solid medium provided homogeneously scattered conidia 
growth and more consistent values of OD measured by a spectrophotometer. With the 
Aspergillus spp., no resistant strain to the new triazoles was found and all MICs for 
isavuconazole were <2 mg/L. MIC values against A. fumigatus (TABLE 8) were similar 
to those reported using either the CLSI method or the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) method (95, 99). My results were a 
little lower than the values reported for the CLSI method, possibly owing to the 
different growth properties of the assay conditions. In our method using a semi-solid 
medium in a flat-bottomed well, the conidia remained in suspension. In the CLSI 
method using a liquid medium in a U-shaped well, the conidia precipitate and form a 
pellet at the bottom of the well. Therefore, with the CLSI method, judgment of the 
endpoint and determination of score 0 at higher concentrations may be easier. The 
strains of Aspergillus spp. tested here were not contemporary clinical isolates. Therefore, 
these strains might not have been exposed to azoles. As a wild-type strain is not 
expected to have acquired resistance to a particular agent such as an azole (95), the 
Aspergillus strains tested can be regarded as wild-type strains. Amino acid substitutions 
in CYP51A at glycine 54 (G54), at G448, and at methionine 220 (M220), and amino 
acid substitution at position 98 of leucine for histidine (L98H) together with tandem 
repeat, as well as high-level expression of a multidrug resistance efflux pump have been 
reported as reasons for azole resistance (96, 99). Understanding the reason for the 
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development of resistance is very important in the development of novel drugs. 
Aspergillus species are generally susceptible to newer triazoles; however, intrinsic and 
acquired resistance have been documented (109). Pfaller et al. (95) reported that new 
triazole resistance amongst A. fumigatus is uncommon but increasing. Verweij et al. 
(109) reviewed acquired azole-resistant A. fumigatus isolated in clinical settings 
throughout Europe and the USA and they considered azole-resistant Aspergillus might 
be more common. Against uncommon fungal species, isavuconazole showed a broad 
antifungal spectrum that included dematiaceous species such as Exophiala, Phialophora, 
and Fonsecaea spp., but not S. schenckii. The four newer azoles tested were not active 
against S. schenckii (TABLE 8). Here I demonstrate that isavuconazole showed very 
good in vitro antifungal activity overall against a broad range of fungi, including 
FLC-resistant Candida spp., Aspergillus spp. and uncommon opportunistic fungal 
species, but showed limited antifungal activity against zygomycete species. With 
Fusarium spp., P. boydii (S. apiospermum), S. prolificans, and zygomycete species, the 
antifungal activities of isavuconazole and ITC was consistent with reports that 
isavuconazole is more active than VRC against zygomycete species but has limited 
activity against Fusarium spp. (FIG. 8) (24, 94).  I compared the in vitro activity of 
isavuconazole with that of VRC using the waterfall plot charts, and each drug 
concentration in plasma after daily dosing to human; 2.6 µg/mL with isavuconazole 
(101) and 1.8 µg/mL with VCR (80, 97). It is important for each drug concentration in 
plasma to be greater than the MIC of fungi. This result suggests that isavuconazole is 
more effective than VRC against zygomycetes infections in human.   
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Similar findings were reported by Guinea et al. (24). Seifert et al. (103) and 
Curfs-Breuker et al. (12) have reported good in vitro activity of isavuconazole against 
yeasts including Candida isolates, and Warn et al. (114) reported in vitro activity of 
isavuconazole against Aspergillus spp. The efficacy of isavuconazole has been 
demonstrated in murine models of disseminated Candida infection (121) and infection 
by Aspergillus flavus (115) and A. fumigates (113). The activity of isavuconazole 
against refractory zygomycetes is of interest in light of the reported low in vitro efficacy 
of VRC (107) and the occurrence of breakthrough zygomycosis during therapy with the 
latter agent (83). The ergosterol synthesis pathway is a validated target of azole 
antifungal agents, and FLC is still an effective agent against sensitive candidiasis.  
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FIG. 8 In vitro activity of isavuconazole compared with that of voriconazole in waterfall plot.
Antifungal activity was drawn in the waterfall plot and ― represents drug concentration in plasma after administration with daily dose.
C.g, Candida glabrata; C.n, Cryptococcus neoformans; T.b, Trichosporon beigelii; Tr+Mic, Trichophyton and Microsporum spp.; 
Blast+Hist, Blastomyces and Histoplasma spp.
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In clinical settings, ITC and VRC are used for infections due to Aspergillus 
species. VRC is used to treat most frequently because of its efficacy against Candida 
species and Aspergillus species, even though VRC shows a limited activity against 
Scedosporium, Fusarium species and zygomycete species. This issue of limited or 
partial activity of azole antifungals prompted me to research the reason why an intrinsic 
resistance is observed in those insensitive species. In this report, although MIC values 
were determined using two endpoints (score 1 and score 0) in partially sensitive or 
resistant strains (TABLE 9), only clinical study results can clarify which endpoint will 
be more relevant to evaluate clinical efficacy.   
 
The text on the mechanism of resistance and FIGURES in the Discussion have been 
omitted pending regulatory approval of Isavuconazole. 
 
 
 
Isavuconazole showed good activity against clinical isolates from Japan. I 
previously reported in vitro susceptibility testing against Japanese clinical isolated 
yeasts. FLC-resistant C. albicans was not isolated but FLC-resistant C. glabrata was 
isolated from two patients who had been treated with FLC over a long period, and these 
isolates were not cross-resistant to isavuconazole in vitro. Candida krusei and C. 
lipolytica had intermediate susceptibility to FLC and were susceptible to all new 
triazoles. Therefore, it is important to diagnose the causative agent from patient when 
determining which antifungal should be used to treat mycoses. 
The high water solubility of isavuconazolium (the prodrug of isavuconazole)  
(90) allows for either parenteral application or oral administration. The results of phase I 
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studies (101, 102) indicate potential for a convenient treatment with both intravenous 
infusion and oral administration for patients during hospitalization and oral 
administration for the outpatient setting. Furthermore, infections due to emerging 
uncommon fungi (3, 24) and intrinsic FLC-resistant or AmB-resistant species have been 
increasing in recent decades. Isavuconazole will be one of the key players against 
invasive fungal infection by such unfavorable pathogens. There is also the possibility of 
use as a prophylactic, especially against Candida urinary tract infections, 
catheter-related candidemia and Aspergillus infections in immunocompromised patients 
who are neutropenic after receiving immunosuppressant medications, anticancer 
chemotherapies, or hematopoietic cell transplantation (16, 122). These results confirmed 
the antifungal spectrum of isavuconazole, showing for the first time that it has activity 
against clinical isolates of Japanese origin as well as against isolates from North 
America and Europe.  
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General Discussion 
 
In epidemiological studies over the past 40 years, visceral mycoses have been 
increasing; in particular, life-threatening severe mycoses are still more than 40% of the 
total visceral mycoses in autopsy cases. During this period, the launch of FLC in 1989 
showed a strong impact to clinical settings for treating Candida infection. Superficial 
infections or esophageal and vaginal infections by Candida albicans was treated very 
frequently, and many patients benefitted from the advantages of this antifungal; 
however, FLC-resistant Candida appeared immediately. From the result of an analysis 
of causative agents in autopsy cases, the decrease of candidiasis after 1989 was 
noticeable. However, aspergillosis has been increasing and continued to do so. Knoke et 
al. also reported the results of epidemiological study of mycoses in autopsy cases and 
insisted on the importance of pathological autopsy for diagnostic and therapeutic 
strategy in the management of fungal diseases (70). Their review of the autopsy rate in 
the western world concluded that the increment of Aspergillus infections are increasing 
and Candida infections are decreasing, just as I reported for Japan (120). 
I mentioned that azole-resistant fungal infections are increasing, and severe 
infections remain at 40% of all mycoses in autopsied patients. The major cause of FLC 
resistance is the induction of the ATP binding cassette (ABC) transporter in Candida 
species, which limits the membrane permeability of FLC into fungal cell plasma. The 
mechanism of FLC resistance in Aspergillus seems to be a low affinity to CYP51 of 
Aspergillus, which means that FLC does not show any efficacy for aspergillosis. 
Furthermore, amino acid substitutions of CYP51 confer azole resistance by changing 
the binding affinity of azole antifungal drugs. As I mentioned before, the amino acid 
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substitution in CYP51A of Aspergillus at glycine 54 (G54), at G448, and at methionine 
220 (M220), and amino acid substitution at position 98 of leucine for histidine (L98H) 
together with tandem repeat, have been reported as reasons for azole resistance (96, 99).  
 
The text concerning about membrane sterols in the General Discussion has been omitted 
pending regulatory approval of Isavuconazole.  
 
The novel triazole antifungal drug isavuconazole showed very potent 
antifungal activity against various medically important fungi such as Candida species, 
Aspergillus species, and Cryptococcus neoformans. Following the research described in 
this thesis, developing this antifungal drug was continued by Basilea Pharmaceurtica 
International AG, a spin-off from F. Hoffmann La-Roche. The end product, 
isavuconazolium salt, is a good water-soluble prodrug that can be used for both 
intravenous injection and oral administration.  
This thesis has described in detail a small portion of the data used in the 
lengthy process of developing a drug. The results of my data analysis revealed that 
many unmet medical needs existed and helped our team to select what was the best 
target at that time. After the best candidate from hundreds of compounds has been 
chosen as the clinical candidate, its activity or efficacy needed to be confirmed in both 
non-clinical and clinical settings. The many non-clinical experiments that were a 
consequence of the data analysis described here were helpful when introducing the new 
drug to doctors and encouraging them to take part in the clinical trials. Additionally, the 
experiments were helpful for preparing the documents for isavuconazole as an 
Investigational New Drug (IND). Currently, isavuconazole is under Phase III studies, 
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one of which is for invasive aspergillosis (SECURE) and which has met the primary 
endpoint. The knowledge that invasive aspergillosis is a life-threatening disease 
primarily afflicting immunocompromised patients and that a new antifungal agent was 
required to treat these critically ill patients. It is gratifying to note that isavuconazole 
will be on the market in the very near future.  
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